127 related articles for article (PubMed ID: 11136385)
1. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system.
Calvez T; Biou M; Costagliola D; Jullien AM; Laurian Y; Rossi F; Rothschild C; Sié P;
Haemophilia; 2001 Jan; 7(1):82-8. PubMed ID: 11136385
[TBL] [Abstract][Full Text] [Related]
2. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
3. FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.
Doncarli A; Demiguel V; Guseva Canu I; Goulet V; Bayart S; Calvez T; Castet S; Dalibard V; Demay Y; Frotscher B; Goudemand J; Lambert T; Milien V; Oudot C; Sannié T; Chambost H;
Eur J Epidemiol; 2019 May; 34(5):521-532. PubMed ID: 30515664
[TBL] [Abstract][Full Text] [Related]
4. Product choice and haemophilia treatment in the Netherlands.
Mauser-Bunschoten EP; Roosendaal G; van den Berg HM
Haemophilia; 2001 Jan; 7(1):96-8. PubMed ID: 11136388
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
[TBL] [Abstract][Full Text] [Related]
6. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
7. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
8. Management of haemophilia in Sweden.
Nilsson IM
Thromb Haemost; 1976 Jun; 35(3):510-21. PubMed ID: 989956
[TBL] [Abstract][Full Text] [Related]
9. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
[TBL] [Abstract][Full Text] [Related]
10. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
Calvez T; Costagliola D
Transfus Clin Biol; 1994; 1(6):427-35. PubMed ID: 7881588
[TBL] [Abstract][Full Text] [Related]
11. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
12. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry.
Fischer K; Ljung R; Platokouki H; Liesner R; Claeyssens S; Smink E; van den Berg HM
Haemophilia; 2014 Jul; 20(4):e280-6. PubMed ID: 24784937
[TBL] [Abstract][Full Text] [Related]
13. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
16. Changing pattern of care of boys with haemophilia in western European centres.
Chambost H; Ljung R;
Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.
Ljung R; Aronis-Vournas S; Kurnik-Auberger K; van den Berg M; Chambost H; Claeyssens S; van Geet C; Glomstein A; Hann I; Hill F; Kobelt R; Kreuz W; Mancuso G; Muntean W; Petrini P; Rosado L; Scheibel E; Siimes M; Smith O; Tusell J
Haemophilia; 2000 Nov; 6(6):619-24. PubMed ID: 11122385
[TBL] [Abstract][Full Text] [Related]
18. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
Hay CRM; Sharpe T; Dolan G;
Haemophilia; 2017 May; 23(3):376-382. PubMed ID: 28026073
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
[No Abstract] [Full Text] [Related]
20. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.
Pollmann H; Externest D; Ganser A; Eifrig B; Kreuz W; Lenk H; Pabinger I; Schramm W; Schwarz TF; Zimmermann R; Zavazava N; Oldenburg J; Klamroth R
Haemophilia; 2007 Mar; 13(2):131-43. PubMed ID: 17286765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
